## Cheng-Ta Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8007985/publications.pdf

Version: 2024-02-01

		126907	168389
158	4,042	33	53
papers	citations	h-index	g-index
160	160	160	6355
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-NaÃ⁻ve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. Cancer Research and Treatment, 2023, 55, 83-93.	3.0	2
2	A hospital cluster of COVID-19 associated with a SARS-CoV-2 superspreading event. Journal of Microbiology, Immunology and Infection, 2022, 55, 436-444.	3.1	10
3	Afatinib treatment in a large realâ€world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. International Journal of Cancer, 2022, 150, 626-635.	5.1	16
4	Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers, 2022, 14, 316.	3.7	3
5	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. Cancers, 2022, 14, 674.	3.7	10
6	An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study. JTO Clinical and Research Reports, 2022, 3, 100292.	1.1	3
7	Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. Cancers, 2022, 14, 977.	3.7	12
8	The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis. Scientific Reports, 2022, 12, 4398.	3.3	6
9	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo <scp>T790M</scp> mutation: A retrospective study of 44 patients. Thoracic Cancer, 2022, 13, 1888-1897.	1.9	8
10	Nuclear p120 catenin is a component of the perichromosomal layer and coordinates sister chromatid segregation during mitosis in lung cancer cells. Cell Death and Disease, 2022, 13, .	6.3	1
11	Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON Journal of Clinical Oncology, 2022, 40, 9035-9035.	1.6	O
12	First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110357.	3.2	12
13	Successful management of COVID-19 induced acute respiratory distress syndrome by extracorporeal membrane oxygenation with 1-year follow-up: A case report. IDCases, 2021, 26, e01281.	0.9	O
14	Roles of lung-recruited monocytes and pulmonary Vascular Endothelial Growth Factor (VEGF) in resolving Ventilator-Induced Lung Injury (VILI). PLoS ONE, 2021, 16, e0248959.	2.5	4
15	Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. JTO Clinical and Research Reports, 2021, 2, 100131.	1.1	4
16	A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. BMC Cancer, 2021, 21, 309.	2.6	4
17	A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy. Oncology and Therapy, 2021, 9, 489-503.	2.6	5
18	Relative COVID-19 Viral Persistence and Antibody Kinetics. Pathogens, 2021, 10, 752.	2.8	9

#	Article	IF	CITATIONS
19	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines, 2021, 9, 689.	4.4	9
20	Total Sleep Time in the Taiwan Obstructive Lung Disease Cohort. International Journal of Environmental Research and Public Health, 2021, 18, 7080.	2.6	0
21	Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer, 2021, 21, 859.	2.6	15
22	Predictors of Invasive Adenocarcinomas among Pure Ground-Glass Nodules Less Than 2 cm in Diameter. Cancers, 2021, 13, 3945.	3.7	13
23	Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. Vaccines, 2021, 9, 1122.	4.4	18
24	Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease. Medicina (Lithuania), 2021, 57, 1160.	2.0	1
25	Infection control operations of a large hospital in Taiwan to prevent nosocomial outbreaks during COVID-19 pandemic. Biomedical Journal, 2021, 44, S8-S14.	3.1	8
26	Downregulation of lumican enhanced mitotic defects and aneuploidy in lung cancer cells. Cell Cycle, 2020, 19, 97-108.	2.6	12
27	Concomitant infection with COVID-19 and Mycoplasma pneumoniae. Biomedical Journal, 2020, 43, 458-461.	3.1	22
28	Severe OSA associated with higher risk of mortality in stage III and IV lung cancer. Journal of Clinical Sleep Medicine, 2020, 16, 1091-1098.	2.6	27
29	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncology, 2020, 16, 2799-2808.	2.4	50
30	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1907-1918.	1.1	85
31	Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19. Thrombosis Research, 2020, 196, 11-14.	1.7	11
32	The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals, 2020, 13, 331.	3.8	14
33	The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers, 2020, 12, 1361.	3.7	39
34	Circulating Tumor Cells as a Tool of Minimal Residual Disease Can Predict Lung Cancer Recurrence: A longitudinal, Prospective Trial. Diagnostics, 2020, 10, 144.	2.6	33
35	The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma. Biomedicines, 2020, 8, 36.	3.2	14
36	Consolidation treatment of durvalumab after chemoradiation in realâ€world patients with stage III unresectable nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 1541-1549.	1.9	28

#	Article	IF	CITATIONS
37	Severe Obstructive Sleep Apnea Associated With Higher Risk of Mortality in Stage III and IV Lung Cancer. Journal of Clinical Sleep Medicine, 2020, , .	2.6	O
38	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences, 2019, 20, 3821.	4.1	116
39	VEGF mediates fat embolism-induced acute lung injury via VEGF receptor 2 and the MAPK cascade. Scientific Reports, 2019, 9, 11713.	3.3	24
40	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncology, 2019, 15, 2905-2914.	2.4	71
41	Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. Targeted Oncology, 2019, 14, 433-440.	3.6	9
42	Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III nonâ€small cell lung cancer: Results of a singleâ€arm prospective cohort study. Thoracic Cancer, 2019, 10, 1683-1691.	1.9	6
43	Frontâ€line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thoracic Cancer, 2019, 10, 2274-2281.	1.9	4
44	Pharyngeal distensibility during expiration is an independent predictor of the severity of obstructive sleep apnoea. Respirology, 2019, 24, 582-589.	2.3	6
45	Cucurbitacin E inhibits the Yesâ€'associated protein signaling pathway and suppresses brain metastasis of human nonâ€'small cell lung cancer in a murine model. Oncology Reports, 2019, 42, 697-707.	2.6	19
46	Cul4A Modulates Invasion and Metastasis of Lung Cancer through Regulation of ANXA10. Cancers, 2019, 11, 618.	3.7	16
47	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. Journal of Thoracic Oncology, 2019, 14, 1255-1265.	1.1	59
48	Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 1158-1166.	1.9	17
49	Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma. Clinical Nuclear Medicine, 2019, 44, e68-e75.	1.3	8
50	Monocytic C-C chemokine receptor 5 expression increases in in vitro intermittent hypoxia condition and in severe obstructive sleep apnea patients. Sleep and Breathing, 2019, 23, 1177-1186.	1.7	9
51	Elevated Serum Markers of Acute Kidney Injury in Patients With Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 2019, 15, 207-213.	2.6	11
52	Prognostic impact of combining whole-body PET/CT and brain PET/MR in patients with lung adenocarcinoma and brain metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 467-477.	6.4	11
53	Downregulation of lumican accelerates lung cancer cell invasion through p120 catenin. Cell Death and Disease, 2018, 9, 414.	6.3	27
54	Stomatin-like protein 2 regulates survivin expression in non-small cell lung cancer cells through $\hat{l}^2$ -catenin signaling pathway. Cell Death and Disease, 2018, 9, 425.	6.3	24

#	Article	IF	CITATIONS
55	Inhibition of yesâ€associated protein downâ€regulates PD‣1 (CD274) expression in human malignant pleural mesothelioma. Journal of Cellular and Molecular Medicine, 2018, 22, 3139-3148.	3.6	43
56	Inhibition of yesâ€associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. Journal of Cellular and Molecular Medicine, 2018, 22, 3073-3085.	3.6	23
57	Accuracy of Presurgical Functional MR Imaging for Language Mapping of Brain Tumors: A Systematic Review and Meta-Analysis. Radiology, 2018, 286, 512-523.	7.3	46
58	Response to afatinib in treatment-na $\tilde{A}$ -ve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Review of Anticancer Therapy, 2018, 18, 81-89.	2.4	29
59	Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. Journal of Thoracic Disease, 2018, 10, 2070-2078.	1.4	18
60	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines, 2018, 6, 114.	3.2	28
61	Impact of prolonged and early bevacizumab treatment on the overall survival of <i>EGFR</i> â€mutant and <i>EGFR</i> â€wild type nonsquamous nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 1648-1655.	1.9	3
62	Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis. Journal of Thoracic Oncology, 2018, 13, e227-e230.	1,1	13
63	Sequential treatment with afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: an observational study. Future Oncology, 2018, 14, 2861-2874.	2.4	90
64	Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2018, 9, 232.	4.8	10
65	Changes in and Determinants of Quality of Life in Patients With Advanced Non-Small-Cell Lung Cancer Undergoing Initial Chemotherapy. The Journal of Nursing Research: JNR, 2017, 25, 203-215.	1.7	14
66	Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes. Annals of Intensive Care, 2017, 7, 9.	4.6	15
67	Dynamic driving pressure associated mortality in acute respiratory distress syndrome with extracorporeal membrane oxygenation. Annals of Intensive Care, 2017, 7, 12.	4.6	54
68	Coinfection and Mortality in Pneumonia-Related Acute Respiratory Distress Syndrome Patients with Bronchoalveolar Lavage. Shock, 2017, 47, 615-620.	2.1	21
69	Nintedanib reduces ventilationâ€augmented bleomycinâ€induced epithelial–mesenchymal transition and lung fibrosis through suppression of the Src pathway. Journal of Cellular and Molecular Medicine, 2017, 21, 2937-2949.	3.6	45
70	The gender difference of snore distribution and increased tendency to snore in women with menopausal syndrome: a general population study. Sleep and Breathing, 2017, 21, 543-547.	1.7	7
71	Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study. Lung Cancer, 2017, 104, 58-64.	2.0	22
72	Design of wearable and wireless multi-parameter monitoring system for evaluating cardiopulmonary function. Medical Engineering and Physics, 2017, 47, 144-150.	1.7	12

#	Article	IF	CITATIONS
73	Design of Wearable Breathing Sound Monitoring System for Real-Time Wheeze Detection. Sensors, 2017, 17, 171.	3.8	83
74	The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations. Oncotarget, 2017, 8, 97602-97612.	1.8	25
75	Feasibility of Radial Endobronchial Ultrasound-Guided Bronchoscopic Cryobiopsy without Fluoroscopy for Lung Parenchymal Lesions. Canadian Respiratory Journal, 2017, 2017, 1-5.	1.6	7
76	Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. Oncotarget, 2017, 8, 1343-1353.	1.8	36
77	Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 75952-75967.	1.8	22
78	Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection. Journal of Thoracic Disease, 2016, 8, 1477-1486.	1.4	7
79	YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget, 2016, 7, 51922-51933.	1.8	94
80	Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. Oncology Letters, 2016, 12, 4598-4604.	1.8	49
81	Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention. Tumor Biology, 2016, 37, 11873-11882.	1.8	4
82	A primer and probe set for detecting multiple types of EGFR exon 19 deletions. Analytical Biochemistry, 2016, 513, 61-67.	2.4	2
83	Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions. Biomedical Journal, 2016, 39, 121-129.	3.1	3
84	Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). Cancer Treatment and Research Communications, 2016, 9, 48-55.	1.7	7
85	Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells. Journal of Cellular and Molecular Medicine, 2016, 20, 1295-1306.	3.6	13
86	Reversibility of albuminuria and continuous positive airway pressure compliance in patients of obstructive sleep apnea syndrome. Medicine (United States), 2016, 95, e4045.	1.0	12
87	TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2155-2165.	6.4	25
88	Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. Oncotarget, 2016, 7, 53299-53308.	1.8	9
89	Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units. BMC Infectious Diseases, 2015, 15, 444.	2.9	21
90	Activation of Src-dependent Smad3 signaling mediates the neutrophilic inflammation and oxidative stress in hyperoxia-augmented ventilator-induced lung injury. Respiratory Research, 2015, 16, 112.	3.6	23

#	Article	IF	CITATIONS
91	Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection. Medicine (United States), 2015, 94, e2013.	1.0	12
92	Total Lesion Glycolysis Determined per RECIST 1.1 Criteria Predicts Survival in EGFR Mutation-Negative Patients With Advanced Lung Adenocarcinoma. Clinical Nuclear Medicine, 2015, 40, e295-e299.	1.3	12
93	Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits. International Journal of COPD, 2015, 10, 767.	2.3	30
94	<i>Antrodia cinnamomea</i> alleviates cisplatin-induced hepatotoxicity and enhances chemo-sensitivity of line-1 lung carcinoma xenografted in BALB/cByJ mice. Oncotarget, 2015, 6, 25741-25754.	1.8	20
95	Gray matter atrophy in narcolepsy: An activation likelihood estimation meta-analysis. Neuroscience and Biobehavioral Reviews, 2015, 59, 53-63.	6.1	27
96	Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy. Critical Care, 2015, 19, 228.	5.8	87
97	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. Journal of Thoracic Oncology, 2015, 10, 793-799.	1.1	199
98	Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells. Oncology Reports, 2015, 34, 3187-3195.	2.6	13
99	Survival Predictors in Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. Annals of Thoracic Surgery, 2015, 99, 243-250.	1.3	42
100	Immediate and Long-term Neurocognitive Outcome in Patients with Obstructive Sleep Apnea Syndrome After Continuous Positive Airway Pressure Treatment. Indian Journal of Otolaryngology and Head and Neck Surgery, 2015, 67, 79-85.	0.9	6
101	The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years oldâ€"Taiwan's PPV vaccination program. Vaccine, 2015, 33, 2897-2902.	3.8	51
102	Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection. Japanese Journal of Clinical Oncology, 2015, 45, 267-273.	1.3	5
103	Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. Lung Cancer, 2015, 90, 472-476.	2.0	14
104	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. British Journal of Cancer, 2015, 113, 1519-1528.	6.4	94
105	The impact of aerosolized mucolytic agents on the airflow resistance of bacterial filters used in mechanical ventilation. Journal of the Formosan Medical Association, 2015, 114, 717-721.	1.7	1
106	Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer. Biomedical Journal, 2015, 38, 329.	3.1	5
107	Circulating Endothelial-Derived Activated Microparticle: A Useful Biomarker for Predicting One-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer. BioMed Research International, 2014, 2014, 1-11.	1.9	37
108	Chronic Obstructive Pulmonary Disease in Stage I Non-small Cell Lung Cancer That Underwent Anatomic Resection: The Role of a Recurrence Promoter. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 407-413.	1.6	19

#	Article	IF	Citations
109	Mechanical ventilation augments bleomycin-induced epithelial–mesenchymal transition through the Src pathway. Laboratory Investigation, 2014, 94, 1017-1029.	3.7	14
110	Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma. Chemotherapy, 2014, 60, 201-210.	1.6	4
111	Mapping Gray Matter Reductions in Obstructive Sleep Apnea: An Activation Likelihood Estimation Meta-Analysis. Sleep, 2014, 37, 167-175.	1.1	84
112	Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. PLoS ONE, 2014, 9, e107160.	2.5	11
113	The utility of surgical lung biopsy in cancer patients with acute respiratory distress syndrome. Journal of Cardiothoracic Surgery, 2013, 8, 128.	1.1	2
114	MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virology Journal, 2013, 10, 241.	3.4	42
115	Improvement of ventilator-induced lung injury by IPS cell-derived conditioned medium via inhibition of PI3K/Akt pathway and IP-10-dependent paracrine regulation. Biomaterials, 2013, 34, 78-91.	11.4	40
116	Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model. International Journal of Oncology, 2013, 43, 1517-1522.	3.3	18
117	Levels of Circulating Microparticles in Lung Cancer Patients and Possible Prognostic Value. Disease Markers, 2013, 35, 301-310.	1.3	48
118	Lumican Regulates Ventilation-Induced Epithelial-Mesenchymal Transition Through Extracelluar Signal-Regulated Kinase Pathway. Chest, 2013, 143, 1252-1260.	0.8	26
119	Suppressing NF-κB and NKRF Pathways by Induced Pluripotent Stem Cell Therapy in Mice with Ventilator-Induced Lung Injury. PLoS ONE, 2013, 8, e66760.	2.5	18
120	Diseases in Patients Coming to a Sleep Center with Symptoms Related to Restless Legs Syndrome. PLoS ONE, 2013, 8, e71499.	2.5	13
121	Ethyl pyruvate reduces ventilation-induced neutrophil infiltration and oxidative stress. Experimental Biology and Medicine, 2012, 237, 720-727.	2.4	14
122	High-Frequency Oscillatory Ventilation for Rescue From Refractory Hypoxemia in a Patient With Transfusion-Related Acute Lung Injury. Respiratory Care, 2012, 57, 798-801.	1.6	2
123	Effects of cardiac output levels on the measurement of transpulmonary thermodilution cardiac output in patients with acute respiratory distress syndrome. Journal of Trauma and Acute Care Surgery, 2012, 73, 1236-1241.	2.1	3
124	Invasive fungal infection among hematopoietic stem cell transplantation patients with mechanical ventilation in the intensive care unit. BMC Infectious Diseases, 2012, 12, 44.	2.9	6
125	Hydroxyethyl starch reduces high stretch ventilation-augmented lung injury via vascular endothelial growth factor. Translational Research, 2011, 157, 293-305.	5.0	20
126	Lumican Expression in Diaphragm Induced by Mechanical Ventilation. PLoS ONE, 2011, 6, e24692.	2.5	7

#	Article	IF	CITATIONS
127	Resolution of Organ Functional Scores to Predict the Outcome in Adult Acute Respiratory Distress Syndrome Patients Receiving High-Frequency Oscillatory Ventilation. Journal of Trauma, 2011, 71, 1536-1542.	2.3	3
128	Cul4A is an oncogene in malignant pleural mesothelioma. Journal of Cellular and Molecular Medicine, 2011, 15, 350-358.	3.6	61
129	Renal replacement therapy in prolonged mechanical ventilation patients with renal failure in Taiwan. Journal of Critical Care, 2011, 26, 600-607.	2.2	12
130	CK2 Inhibitors Enhance the Radiosensitivity of Human Non-Small Cell Lung Cancer Cells Through Inhibition of Stat3 Activation. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 381-388.	1.0	23
131	Second primary esophageal or lung cancer in patients with head and neck carcinoma in Taiwan: incidence and risk in relation to primary index tumor site. Journal of Cancer Research and Clinical Oncology, 2011, 137, 115-123.	2.5	34
132	Low-molecular-weight heparin reduces hyperoxia-augmented ventilator-induced lung injury via serine/threonine kinase-protein kinase B. Respiratory Research, 2011, 12, 90.	3.6	29
133	Obstructive sleep apnea: a stand-alone risk factor for chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 2244-2250.	0.7	103
134	Transcriptional regulation of the ORF61 and ORF60 genes of Kaposi's sarcoma-associated herpesvirus. Virology, 2010, 397, 311-321.	2.4	17
135	The prevalence of restless legs syndrome in Taiwanese adults. Psychiatry and Clinical Neurosciences, 2010, 64, 170-178.	1.8	70
136	Functional Polymorphism of the CK2α Intronless Gene Plays Oncogenic Roles in Lung Cancer. PLoS ONE, 2010, 5, e11418.	2.5	31
137	Gefitinib as Firstâ€ine Therapy for Advanced or Metastatic Nonâ€small Cell Lung Cancer Patients in Southern Taiwan. Kaohsiung Journal of Medical Sciences, 2010, 26, 1-7.	1.9	0
138	Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. BMC Cancer, 2009, 9, 135.	2.6	26
139	WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. Journal of Cancer Research and Clinical Oncology, 2009, 135, 919-924.	2.5	30
140	Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis. Experimental Eye Research, 2009, 89, 678-685.	2.6	22
141	Pulmonary cryptococcosis: Clinical, radiographical and serological markers of dissemination. Respirology, 2008, 13, 247-251.	2.3	28
142	A Novel Vector System for Gene Transfer into the Cornea Using a Partially Dried Plasmid Expressing 18 Basic Fibroblast Growth Factor–Synthetic Amphiphile INTeraction-18 (SAINT-18) Complex. Current Eye Research, 2008, 33, 839-848.	1.5	4
143	Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells. Nature Precedings, 2008, , .	0.1	0
144	Wnt Inhibitory Factor-1 Gene Transfer Inhibits Melanoma Cell Growth. Human Gene Therapy, 2007, 18, 379-386.	2.7	49

#	Article	IF	Citations
145	Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochemical and Biophysical Research Communications, 2006, 341, 635-640.	2.1	63
146	The sensitivity of human mesenchymal stem cells to ionizing radiation. International Journal of Radiation Oncology Biology Physics, 2006, 66, 244-253.	0.8	163
147	p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1461-1472.	0.8	19
148	Acute Pyelonephritis Associated with Transudative Pleural Effusion in a Middle-Aged Woman without Urinary Tract Obstruction. Medical Principles and Practice, 2006, 15, 309-311.	2.4	6
149	Caffeic acid phenethyl ester decreases acute pneumonitis after irradiation in vitro and in vivo. BMC Cancer, 2005, 5, 158.	2.6	44
150	Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Research, 2005, 25, 2049-54.	1.1	20
151	Early Referral as an Independent Predictor of Clinical Outcome in Endâ€Stage Renal Disease on Hemodialysis and Continuous Ambulatory Peritoneal Dialysis. Renal Failure, 2004, 26, 531-537.	2.1	27
152	Improved Anemia and Reduced Erythropoietin Need by Medical or Surgical Intervention of Secondary Hyperparathyroidism in Hemodialysis Patients. Renal Failure, 2004, 26, 289-295.	2.1	32
153	Most Common Intoxication in Nephrology Ward Organophosphate Poisoning. Renal Failure, 2004, 26, 349-354.	2.1	18
154	LV Mass Index Significantly Impacts on Patient and Renal Outcomes in Patients with Coronary Artery Bypass Grafting and Poor Left-Ventricular Function. Renal Failure, 2003, 25, 287-295.	2.1	5
155	A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and) Tj ETQq1 1 C	.784314 r	gBT/Overloc
156	Adenovirus-Mediated p14ARF Gene Transfer in Human Mesothelioma Cells. Journal of the National Cancer Institute, 2000, 92, 636-641.	6.3	120
157	Tuberculin purified protein derivative up-regulates the telomerase activity of peripheral blood mononuclear cells from patients with pulmonary tuberculosis. Life Sciences, 1999, 64, 1383-1391.	4.3	4
158	Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction. Respiratory Medicine, 1995, 89, 121-128.	2.9	32